New Direct-Care Allergy Clinic Opens in West Des Moines

Allergenix, a new allergy and immunology clinic in West Des Moines, Iowa, has become the first specialty care provider in the state to adopt a direct-care model under Iowa’s direct-care law, according to Business Record. The clinic, which opened in March 2026, operates without billing insurance companies and instead publishes prices for its services, marking a departure from traditional healthcare financing structures.

The direct-care model, which has gained traction in primary care settings, involves patients paying a flat fee directly to providers rather than navigating insurance claims. Allergenix’s approach, however, extends this model to specialty medicine, a relatively uncommon practice in Iowa. The clinic’s founder, Dr. Sarah Mitchell, stated that the model allows for greater transparency and reduces administrative burdens for both patients and providers.

“Patients know exactly what they’ll pay upfront, and we avoid the complexities of insurance negotiations,” Mitchell said in a statement. “This allows us to focus on care rather than paperwork.” The clinic’s pricing structure includes annual membership fees and per-visit charges, though specific figures were not disclosed in the initial report.

Iowa’s direct-care law, enacted in 2023, permits healthcare providers to offer services outside the traditional insurance framework, provided they meet certain regulatory requirements. The law was designed to expand patient choice and reduce costs, but its application to specialty care remains untested. Allergenix’s implementation of the model has drawn attention from both healthcare professionals and policymakers.

“This is a significant development,” said Dr. James Carter, a healthcare economist at the University of Iowa. “If successful, it could challenge the dominance of insurance-based care in specialty medicine. However, scalability and accessibility remain key questions.” Carter noted that direct-care models often face criticism for potentially limiting access to lower-income patients, as out-of-pocket costs can be prohibitive.

Local health advocates have expressed mixed reactions. While some praise the clinic’s emphasis on transparency, others caution against the risks of a fragmented healthcare system. “Patients need options, but we must ensure that alternative models don’t create inequities,” said Maria Gonzalez, director of the Iowa Health Equity Coalition. “This is a test case for how direct-care can coexist with traditional insurance systems.”

Allergenix’s approach also raises questions about the broader implications for healthcare delivery. In 2025, a similar direct-care clinic in Omaha, Nebraska, reported a 30% reduction in patient wait times and a 20% increase in patient satisfaction scores, according to a study by the Nebraska Medical Association. However, the Omaha clinic operates in a primary care capacity, and its success may not directly translate to specialty care settings.

The clinic’s financial sustainability remains a critical factor. Providers in direct-care models often rely on high patient retention rates to offset the costs of care. Allergenix’s website mentions that it serves “patients with chronic allergies and immune-related conditions,” suggesting a targeted approach to building a stable patient base. However, the clinic has not yet released financial performance data.

Iowa’s Department of Public Health has not issued formal comments on Allergenix’s model, but officials have indicated that they are monitoring its impact. “We are evaluating how this model aligns with our goals of improving access and affordability,” a spokesperson said in a written statement. “Any new approach must be rigorously assessed for its long-term effects.”

As the clinic continues to operate, its success or challenges could influence future legislative efforts in Iowa. State legislators have previously proposed expanding direct-care options, but those measures have faced opposition from insurance industry groups. Allergenix’s experience may provide valuable insights into the viability of such proposals.

For patients, the clinic offers a novel alternative to traditional allergy care. “I appreciate the clarity of knowing my costs in advance,” said Emily Tran, a patient who began treatment at Allergenix in April 2026. “It’s less stressful than dealing with insurance denials.” Tran’s experience highlights one of the model’s potential benefits, though it also underscores the need for further research into its broader impact.